Molecular Diagnostic Tool Identifies Genetic Fingerprint Behind Prostate Cancer Spread
Canadian researchers have made a significant advance in prostate cancer care, discovering a genetic fingerprint that explains why up to 30 percent of men with apparently curable localized prostate cancer go on to develop aggressive disease that spreads after surgery or radiotherapy. The findings, published in Nature, bring scientists closer to a molecular diagnostic tool that could transform how oncologists make treatment decisions from the very first appointment.
The research was led by Dr. Robert Bristow, clinician scientist at the Princess Margaret Cancer Centre, University Health Network, alongside co principal investigator Dr. Paul Boutros from the Ontario Institute for Cancer Research. Their work analyzed the tumors of 500 Canadian men with localized, non inherited prostate cancer using specialized DNA sequencing techniques designed to capture the full genetic complexity of each individual cancer.
The Problem With Current Prostate Cancer Diagnosis
Most men with prostate cancer present with localized disease that appears potentially curable. Yet more than 200,000 men die of prostate cancer worldwide each year — many of them in cases where the disease seemed manageable at the time of initial treatment. The gap between early diagnosis and fatal outcome reflects a fundamental limitation of current clinical tools: they cannot reliably identify which men already have microscopic spread outside the prostate at the time of diagnosis.
Without this information, oncologists must make treatment decisions based on population level risk categories rather than the specific biological behavior of each individual patient’s cancer. A molecular diagnostic tool capable of reading that biological behavior at the genetic level would change the equation entirely.
What the Genetic Fingerprint Reveals
Using state of the art DNA sequencing, the research team identified genetic patterns — fingerprints — within prostate tumors that accurately distinguish men whose cancer responds well to surgery or radiotherapy from those whose disease has already begun to spread. According to Dr. Bristow, these genetic fingerprints had high accuracy in discerning which patients do well with standard local treatment and which already show early signs of disease spread beyond the prostate gland.
This precision gives clinicians something they have never had before: molecular level insight into treatment response and disease trajectory at the point of diagnosis. Rather than waiting to see whether a patient’s cancer returns after treatment, a validated molecular diagnostic tool based on these findings could allow personalized therapy decisions to be made upfront.
“This information gives us new precision about the treatment response of men with prostate cancer, and important clues as to how to better treat one set of men versus the other to improve cure rates overall,” Dr. Bristow said.
A Related Discovery About Inherited Prostate Cancer
Alongside the Nature study, a companion paper published simultaneously in Nature Communications addressed a different but equally important aspect of prostate cancer genetics. Drs. Bristow and Boutros identified the genetic mechanisms that explain why BRCA2 inherited disease turns lethal in rare cases where men carry a mutation in the BRCA2 gene — a mutation that impairs the cell’s ability to repair DNA damage.
This parallel discovery extends the relevance of the molecular diagnostic tool concept beyond the general population to the subset of men with inherited prostate cancer, where aggressive disease and limited treatment options make early genetic identification even more critical.
Building on a Decade of Genomic Research
The findings published in Nature are the latest in a series of landmark discoveries from the Canadian Prostate Cancer Genome Network (CPC GENE), the world’s leading prostate cancer sequencing program co led by Drs. Bristow and Boutros. Their previous work includes the first molecular portrait of localized multifocal prostate cancer and the identification of a new gene subgroup driving it, published in Nature Genetics in 2015, as well as the development of a genetic test to identify men at highest risk for cancer recurrence after local treatment, published in Lancet Oncology in 2014.
Each of these discoveries has contributed to a growing body of genomic knowledge that makes the translation of a clinical molecular diagnostic tool increasingly achievable in the near term.
What Comes Next
The immediate next step is validating these findings in a larger patient cohort. Dr. Bristow confirmed that the team will be testing an additional 500 men over the next two to three years, with the goal of translating the genetic fingerprint research into a molecular diagnostic tool ready for routine clinical use.
“We will soon be able to identify in the clinic the exact genetic state of a man’s cancer and react on a patient to patient basis to cure more men worldwide,” Dr. Bristow said.
The richness of the genomic data generated by this research also positions the team to further refine risk stratification, sorting individual patients into more precise groups based on their likelihood of disease spread — and developing targeted therapies tailored to the specific genetic profile of each man’s cancer.
For more information on active prostate cancer research and clinical studies, visit ClinicalTrials.gov and the Prostate Cancer Foundation.
Participate in Clinical Research With FOMAT
At FOMAT Medical, we support Phase I through Phase IV clinical studies across multiple therapeutic areas throughout the United States, including oncology and precision medicine research. Advances like this molecular diagnostic tool depend on the clinical trial participation of patients willing to contribute to the science that will improve cancer outcomes for future generations.
If you or someone you know may be interested in joining an active clinical study, explore our currently available trials.